Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Charmsaz

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Oncogene|January 26, 2018
Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancerAlacoque L Browne, Sara Charmsaz, Damir Varešlija, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2018
Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast CancerElspeth Ward, Damir Varešlija, Sara Charmsaz, et al.
Cancer Communications (London, England)|January 20, 2023
Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancerStephen Keelan, Mihaela Ola, Sara Charmsaz, et al.
Oncotarget|April 16, 2016
Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastomaBrett W Stringer, Jens Bunt, Bryan W Day, et al.
Neuro-Oncology|August 18, 2011
ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1Bryan W Day, Brett W Stringer, Mark D Spanevello, et al.
BMC Medicine|November 19, 2020
ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasisSara Charmsaz, Ben Doherty, Sinéad Cocchiglia, et al.
BMC Medicine|December 13, 2025
Correction: ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasisSara Charmsaz, Ben Doherty, Sinéad Cocchiglia, et al.
Cancer Cell|February 16, 2013
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiformeBryan W Day, Brett W Stringer, Fares Al-Ejeh, et al.
Oncogene|January 9, 2021
Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotypeDamir Varešlija, Elspeth Ward, Siobhan P Purcell, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Oncogene|January 26, 2018
Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancerAlacoque L Browne, Sara Charmsaz, Damir Varešlija, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2018
Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast CancerElspeth Ward, Damir Varešlija, Sara Charmsaz, et al.
Cancer Communications (London, England)|January 20, 2023
Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancerStephen Keelan, Mihaela Ola, Sara Charmsaz, et al.
Oncotarget|April 16, 2016
Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastomaBrett W Stringer, Jens Bunt, Bryan W Day, et al.
Neuro-Oncology|August 18, 2011
ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1Bryan W Day, Brett W Stringer, Mark D Spanevello, et al.
BMC Medicine|November 19, 2020
ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasisSara Charmsaz, Ben Doherty, Sinéad Cocchiglia, et al.
BMC Medicine|December 13, 2025
Correction: ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasisSara Charmsaz, Ben Doherty, Sinéad Cocchiglia, et al.
Cancer Cell|February 16, 2013
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiformeBryan W Day, Brett W Stringer, Fares Al-Ejeh, et al.
Oncogene|January 9, 2021
Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotypeDamir Varešlija, Elspeth Ward, Siobhan P Purcell, et al.
Pageof 2